ArticleJournal of physiology and biochemistry2014
Histopathological findings of the pancreas, liver, and carbohydrate metabolizing enzymes in STZ-induced diabetic rats improved by administration of myrtenal.
Article in Journal of physiology and biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Myrtenal Ameliorates Ischemic Brain Injury Diabetic and Non-Diabetic Rats.Neurochemical research · 2025Article
- Article
- Myrtenal Pretreatment Exerts a Protective Effect Against Renal Ischemia-Reperfusion Injury in Rats.Journal of biochemical and molecular toxicology · 2025Article
- Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes.PloS one · 2023Article
- Use of Monoterpenes as Potential Therapeutics in Diabetes Mellitus: A Prospective Review.Advances in pharmacological and pharmaceutical sciences · 2023Review
- Metabolomics and biochemical insights on the regulation of aging-related diabetes by a low-molecular-weight polysaccharide from green microalgaFood chemistry: X · 2022Article
- In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update.Molecules (Basel, Switzerland) · 2021Review
- Fustin ameliorates hyperglycemia in streptozotocin induced type-2 diabetes via modulating glutathione/Superoxide dismutase/Catalase expressions, suppress lipid peroxidation and regulates histopathological changes.Saudi journal of biological sciences · 2021Article
- Monoterpenes and Their Derivatives-Recent Development in Biological and Medical Applications.International journal of molecular sciences · 2020Review
- Synthesis and Cytotoxic Analysis of Novel Myrtenyl Grafted Pseudo-Peptides Revealed Potential Candidates for Anticancer Therapy.Molecules (Basel, Switzerland) · 2020Article
- Antidiabetic effects of a lipophilic extract obtained from flowers ofFood & nutrition research · 2020Article
- Biosynthesized ZnO-NPs fromBiomolecules · 2019Article
- Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight.International journal of molecular sciences · 2017Review
- Geraniol, a natural monoterpene, ameliorates hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats.Pharmaceutical biology · 2017Article
- Therapeutic effects of pentoxifylline on diabetic heart tissue via NOS.Anatolian journal of cardiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the efficacy of myrtenal, a natural monoterpene, for its antihyperglycemic effects and β cell protective properties in streptozotocin (STZ)-induced diabetic rats. Oral administration of myrtenal at doses of 20, 40, and 80 mg/kg body weight to diabetic rats for 28 days resulted in a significant reduction (P < 0.05) in the levels of plasma glucose, glycosylated hemoglobin (HbA1c), and an increase in the levels of insulin and hemoglobin (Hb). Protection of body weight loss of diabetic rats by myrtenal was noted. The altered activities of the key metabolic enzymes involved in carbohydrate metabolism such as hexokinase, glucose-6-phosphatase, fructose-1,6-bisphosphatase, glucose-6-phosphate dehydrogenase, and hepatic enzymes AST, ALT, and ALP levels of diabetic rats were significantly improved by the administration of myrtenal in STZ-induced diabetic rats. Moreover, myrtenal treatment improved hepatic and muscle glycogen content in diabetic rats. Histopathological studies further revealed that the reduced islet cells were restored to near-normal conditions on treatment with myrtenal in STZ-induced diabetic rats. An alteration in liver architecture was also prevented by myrtenal treatment. Our results suggest that myrtenal possess antihyperglycemic and β cell protective effects. Hence, myrtenal could be considered as a potent phytochemical for development as a new antidiabetic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.